Clinical Trial Update: A Study of Peginterferon Alfa-2a [PEGASYS] in Patients With Chronic Hepatitis B Who Are HBeAg Positive [Phase 4]

View source ↗

Summary

This document reports the completion of a Phase 4 trial studying pegylated interferon alfa-2a (Pegasys) in HBeAg-positive chronic hepatitis B patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Pegasys (pegylated interferon alfa-2a)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Hepatitis B, Chronic | Phase 4 | Status: COMPLETED